Details of the Drug Combination

General Information of Drug Combination (ID: DC3KNKN)

Drug Combination Name
Lestaurtinib Ispinesib
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Lestaurtinib   DMQ2AIJ Ispinesib   DMP2BWX
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 15.627
Bliss Independence Score: 15.146
Loewe Additivity Score: 0.315
LHighest Single Agent (HSA) Score: 13.236

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lestaurtinib
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved (orphan drug) [2]
Myeloid leukaemia 2B33.1 Phase 3 [2]
Psoriasis vulgaris EA90 Phase 2/3 [2]
Lestaurtinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of Ispinesib
Disease Entry ICD 11 Status REF
Head and neck cancer 2D42 Phase 2 [3]
Ovarian cancer 2C73 Phase 2 [3]
Renal cell carcinoma 2C90 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Ispinesib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Kinesin-like protein KIF11 (KIF11) TTTRP0H KIF11_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
3 ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
4 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
5 Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63.